JP2016509864A5 - - Google Patents

Download PDF

Info

Publication number
JP2016509864A5
JP2016509864A5 JP2015562504A JP2015562504A JP2016509864A5 JP 2016509864 A5 JP2016509864 A5 JP 2016509864A5 JP 2015562504 A JP2015562504 A JP 2015562504A JP 2015562504 A JP2015562504 A JP 2015562504A JP 2016509864 A5 JP2016509864 A5 JP 2016509864A5
Authority
JP
Japan
Prior art keywords
segment
seq
virus
identity
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015562504A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016509864A (ja
JP6525469B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2014/059729 external-priority patent/WO2014141125A2/en
Publication of JP2016509864A publication Critical patent/JP2016509864A/ja
Publication of JP2016509864A5 publication Critical patent/JP2016509864A5/ja
Application granted granted Critical
Publication of JP6525469B2 publication Critical patent/JP6525469B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015562504A 2013-03-13 2014-03-13 インフルエンザb型ウイルス再集合 Active JP6525469B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361779888P 2013-03-13 2013-03-13
US61/779,888 2013-03-13
PCT/IB2014/059729 WO2014141125A2 (en) 2013-03-13 2014-03-13 Influenza virus reassortment

Publications (3)

Publication Number Publication Date
JP2016509864A JP2016509864A (ja) 2016-04-04
JP2016509864A5 true JP2016509864A5 (enExample) 2017-04-20
JP6525469B2 JP6525469B2 (ja) 2019-06-05

Family

ID=50440715

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015562504A Active JP6525469B2 (ja) 2013-03-13 2014-03-13 インフルエンザb型ウイルス再集合

Country Status (13)

Country Link
US (2) US10232031B2 (enExample)
EP (1) EP2968512A2 (enExample)
JP (1) JP6525469B2 (enExample)
KR (1) KR20150130344A (enExample)
CN (2) CN111334530A (enExample)
AU (2) AU2014229255B2 (enExample)
BR (1) BR112015021880A2 (enExample)
CA (1) CA2905612A1 (enExample)
HK (1) HK1218511A1 (enExample)
IL (1) IL240936B (enExample)
MX (1) MX372963B (enExample)
SG (1) SG11201507454XA (enExample)
WO (1) WO2014141125A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012011300A (es) 2010-03-30 2012-11-29 Sinai School Medicine Vacunas del virus de influenza y usos de las mismas.
HK1200102A1 (en) 2011-09-20 2015-07-31 西奈山医学院 Influenza virus vaccines and uses thereof
NZ627796A (en) 2012-12-18 2017-07-28 Icahn School Med Mount Sinai Influenza virus vaccines and uses thereof
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
EP3247389A4 (en) 2015-01-23 2019-10-30 Icahn School of Medicine at Mount Sinai INFLUENZAVIRUSSCHUTZIMPFPLÄNE
KR20180035807A (ko) 2015-06-26 2018-04-06 세퀴러스 유케이 리미티드 항원적으로 매치된 인플루엔자 백신
WO2017005880A1 (en) 2015-07-07 2017-01-12 Seqirus UK Limited Influenza potency assays
MX2018015755A (es) 2016-06-15 2019-08-29 Icahn School Med Mount Sinai Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
CA3058652A1 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
JP7432506B2 (ja) 2017-10-30 2024-02-16 武田薬品工業株式会社 脂質エンベロープウイルスを不活化するための環境適合性の界面活性剤
CN108018300B (zh) * 2017-11-21 2020-08-28 浙江迪福润丝生物科技有限公司 区分免疫和感染动物h7亚型禽流感疫苗株及其制备方法和应用
US12364746B2 (en) 2018-06-21 2025-07-22 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
CA3137160A1 (en) 2019-04-24 2020-10-29 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
WO2021173965A1 (en) 2020-02-28 2021-09-02 Massachusetts Institute Of Technology Identification of variable influenza residues and uses thereof
CN114262694B (zh) * 2021-12-06 2023-11-03 军事科学院军事医学研究院军事兽医研究所 以B型流感病毒为载体的SARS-CoV-2疫苗候选株及其构建方法和应用
CN116063409A (zh) * 2022-09-09 2023-05-05 中山大学·深圳 一种乙型流感Mosaic重组蛋白、重组质粒及其构建方法和应用
CN118978590B (zh) * 2024-10-12 2025-01-21 北京溯本源和生物科技有限公司 一种利用重组流感病毒免疫小鼠制备杂交瘤单抗的方法及应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
ES2301241T3 (es) 1998-06-12 2008-06-16 Mount Sinai School Of Medicine Of The City University Of New York Virus de influenza a atenuados, y composiciones inmunogenicas y formulaciones de vacunas que los contienen.
IT1307930B1 (it) * 1999-01-26 2001-11-29 Sinco Ricerche Spa Articoli trasparenti in resina poliestere (mg32).
KR20020038771A (ko) 1999-09-24 2002-05-23 장 스테판느 비내 인플루엔자 바이러스 백신
EP1260581B1 (en) 2000-03-03 2010-07-07 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
ES2327103T3 (es) * 2000-09-25 2009-10-26 Polymun Scientific Immunbiologische Forschung Gmbh Vacuna viva de influenzavirus y procedimiento de fabricacion.
WO2002024878A2 (en) 2000-09-25 2002-03-28 Bayer Aktiengesellschaft Human e3 ubiquitin protein ligase-like enzyme
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
US20040096463A1 (en) 2001-02-23 2004-05-20 Nathalie Garcon Novel vaccine
DE60239594D1 (de) 2001-02-23 2011-05-12 Glaxosmithkline Biolog Sa Influenza vakzinzusammensetzungen zur intradermaler verabreichung
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
JP5393978B2 (ja) 2004-04-05 2014-01-22 ゾエティス・ピー・エルエルシー マイクロ流動化された水中油型乳剤及びワクチン組成物
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
NZ551640A (en) 2004-05-20 2010-05-28 Id Biomedical Corp Process for the production of an influenza vaccine
HUE025727T2 (en) * 2004-05-24 2016-04-28 Medimmune Llc Multi-plasmid system for producing influenza virus
DK2368975T3 (en) 2004-12-23 2015-01-05 Medimmune Llc Non-tumorigenic MDCK cell line for the propagation of viruses
ES2527503T3 (es) * 2005-03-08 2015-01-26 Medimmune, Llc Virus influenza reordenantes
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
US20060286591A1 (en) 2005-06-21 2006-12-21 Medimmune Vaccines, Inc. Methods and compositions for expressing negative-sense viral RNA in canine cells
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
WO2007052163A2 (en) 2005-11-01 2007-05-10 Novartis Vaccines And Diagnostics Gmbh & Co Kg Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment
NZ567979A (en) 2005-11-04 2012-02-24 Novartis Vaccines & Diagnostic Adjuvanted influenza vaccines including a cytokine-inducing agents which is an agonist of Toll-Like Receptor 7
US20090220541A1 (en) 2005-11-04 2009-09-03 Novartis Vaccines And Diagnostics Srl Emulsions with free aqueous-phase surfactant for adjuvanting split influenza vaccines
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
CN1810961B (zh) * 2006-02-22 2010-05-12 中国人民解放军军事医学科学院微生物流行病研究所 一种重组流感病毒及其制备方法与应用
CN101472941B (zh) * 2006-03-31 2017-08-08 沃弗-威斯康星校友研究基金会 用于疫苗的高滴度重组流感病毒
JP5491173B2 (ja) 2006-04-19 2014-05-14 メディミューン,エルエルシー イヌ細胞中でマイナス鎖ウイルスrnaを発現させるための方法および組成物
ES2397714T3 (es) 2006-10-12 2013-03-08 Glaxosmithkline Biologicals S.A. Vacuna que comprende un adyuvante de emulsión de aceite en agua
PL2121011T3 (pl) 2006-12-06 2014-10-31 Novartis Ag Szczepionki zawierające antygeny czterech szczepów wirusa grypy
EP2045323A1 (en) 2007-10-05 2009-04-08 Avir Green Hills Biotechnology Research Development Trade Ag Linear expression constructs for production of influenza virus particles
RU2523587C2 (ru) 2008-07-11 2014-07-20 МЕДИММЬЮН, ЭлЭлСи Варианты гемагглютинина и нейрамидазы вируса гриппа
CN102257135B (zh) 2008-12-16 2017-06-09 纳米医疗公司 流感疫苗的生产
EP2401384B1 (en) 2009-05-21 2012-10-03 Novartis AG Reverse genetics using non-endogenous pol i promoters
EP2459722B1 (en) 2009-07-31 2017-09-06 Seqirus UK Limited Reverse genetics systems
WO2011048560A1 (en) 2009-10-20 2011-04-28 Novartis Ag Improved reverse genetics methods for virus rescue
US8945904B2 (en) 2010-05-21 2015-02-03 Novartis Ag Influenza virus reassortment

Similar Documents

Publication Publication Date Title
JP2015119730A5 (enExample)
JP2016521553A5 (enExample)
JP2016501020A5 (enExample)
Milián et al. Current and emerging cell culture manufacturing technologies for influenza vaccines
Horimoto et al. Enhanced growth of seed viruses for H5N1 influenza vaccines
JP2019011344A5 (enExample)
Petiot et al. Influenza viruses production: Evaluation of a novel avian cell line DuckCelt®-T17
WO2008156681A2 (en) Adenoviral vectors for influenza virus production
JP2017189179A5 (enExample)
JP2018064493A (ja) Mdck細胞を用いたインフルエンザウイルスの増殖方法
Li et al. Screening of the high yield influenza B virus on MDCK cell and cloning of its whole genome
Van Wielink et al. Adaptation of a Madin–Darby canine kidney cell line to suspension growth in serum-free media and comparison of its ability to produce avian influenza virus to Vero and BHK21 cell lines
Minor et al. Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK
Chen et al. Partial and full PCR-based reverse genetics strategy for influenza viruses
Mostafa et al. The PB1 segment of an influenza A virus H1N1 2009pdm isolate enhances the replication efficiency of specific influenza vaccine strains in cell culture and embryonated eggs
Johnson et al. Identification of influenza A/PR/8/34 donor viruses imparting high hemagglutinin yields to candidate vaccine viruses in eggs
CN108018300B (zh) 区分免疫和感染动物h7亚型禽流感疫苗株及其制备方法和应用
CN113853215B (zh) 高生长流感病毒
US11883483B2 (en) Method for preparing influenza working virus seed stock, method for preparing influenza vaccine using same seed stock, and virus seed stock prepared by same method
Shao et al. An efficient and rapid influenza gene cloning strategy for reverse genetics system
CN104195154A (zh) 新城疫病毒Mukteswar中等毒力疫苗株反向遗传操作系统及其应用
Zhou et al. High-yield production of a stable Vero cell-based vaccine candidate against the highly pathogenic avian influenza virus H5N1
Koudstaal et al. Suitability of PER. C6® cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics
Suzuki et al. Development of an influenza A master virus for generating high-growth reassortants for A/Anhui/1/2013 (H7N9) vaccine production in qualified MDCK cells
MX2015001499A (es) Produccion de virus infecciosos de influenza.